

Anita Sveen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1542362/publications.pdf>

Version: 2024-02-01

47
papers

2,300
citations

394286

19
h-index

233338

45
g-index

48
all docs

48
docs citations

48
times ranked

4399
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. <i>Molecular Cancer</i> , 2017, 16, 116.	7.9	232
2	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. <i>Scientific Reports</i> , 2017, 7, 16618.	1.6	229
3	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
4	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
5	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. <i>Gut</i> , 2012, 61, 1560-1567.	6.1	179
6	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	3.2	177
7	ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6001-6010.	3.2	109
8	Combination therapies with HSP90 inhibitors against colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 240-247.	3.3	81
9	Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. <i>Genome Medicine</i> , 2011, 3, 32.	3.6	73
10	Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. <i>Genome Medicine</i> , 2017, 9, 46.	3.6	71
11	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. <i>Cancer Letters</i> , 2017, 385, 150-159.	3.2	70
12	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
13	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225.	1.5	64
14	Phospholipase C Isozymes Are Deregulated in Colorectal Cancer — Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. <i>PLoS ONE</i> , 2011, 6, e24419.	1.1	58
15	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	2.9	41
16	Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. <i>Molecular Oncology</i> , 2018, 12, 1639-1655.	2.1	40
17	Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. <i>International Journal of Cancer</i> , 2019, 144, 2843-2853.	2.3	33
18	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 59.	1.7	29

#	ARTICLE	IF	CITATIONS
19	Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?. <i>Clinical Cancer Research</i> , 2013, 19, 6669-6677.	3.2	27
20	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 841-847.	2.3	26
21	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020, 59, 102923.	2.7	22
22	The exon-level biomarker <i>SLC39A14</i> has organ-confined cancer-specificity in colorectal cancer. <i>International Journal of Cancer</i> , 2012, 131, 1479-1485.	2.3	20
23	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. <i>Oncogene</i> , 2019, 38, 6109-6122.	2.6	20
24	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e26-e47.	1.0	20
25	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. <i>Oncogenesis</i> , 2019, 8, 35.	2.1	19
26	Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. <i>BMC Genomics</i> , 2014, 15, 672.	1.2	15
27	Novel RNA variants in colorectal cancers. <i>Oncotarget</i> , 2015, 6, 36587-36602.	0.8	15
28	Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. <i>Molecular Oncology</i> , 2020, 14, 1016-1027.	2.1	15
29	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2340-2346.	0.5	14
30	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. <i>Cancer Letters</i> , 2020, 469, 246-255.	3.2	12
31	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. <i>Modern Pathology</i> , 2018, 31, 1694-1707.	2.9	11
32	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000523.	2.0	11
33	Genomic and prognostic heterogeneity among <i>RAS/BRAF</i> ^{V600E} / <i>TP53</i> co-mutated resectable colorectal liver metastases. <i>Molecular Oncology</i> , 2021, 15, 830-845.	2.1	11
34	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021, 13, 143.	3.6	10
35	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. <i>Modern Pathology</i> , 2022, 35, 1236-1246.	2.9	8
36	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. <i>Blood Advances</i> , 2020, 4, 1859-1866.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. <i>Acta Oncologica</i> , 2021, 60, 921-930.	0.8	7
38	Observed correlation between the expression levels of catalytic subunit, C $\hat{1}$ 2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 111.e1-111.e8.	0.8	6
39	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020, 5, e001040.	2.0	6
40	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. <i>Journal of Translational Medicine</i> , 2021, 19, 384.	1.8	6
41	TIN: An R Package for Transcriptome Instability Analysis. <i>Cancer Informatics</i> , 2015, 14, CIN.S31363.	0.9	4
42	Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability. <i>International Journal of Cancer</i> , 2021, 148, 1652-1657.	2.3	4
43	The expressed mutational landscape of microsatellite stable colorectal cancers. <i>Genome Medicine</i> , 2021, 13, 142.	3.6	4
44	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. <i>Cancer Gene Therapy</i> , 2022, 29, 1276-1284.	2.2	3
45	Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188682.	3.3	1
46	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. <i>Journal of Clinical Oncology</i> , 2016, 34, 604-604.	0.8	0
47	Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling. <i>Blood</i> , 2019, 134, 1497-1497.	0.6	0